Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia - Trial NCT05480501
Access comprehensive clinical trial information for NCT05480501 through Pure Global AI's free database. This Phase 1 trial is sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd. and is currently Recruiting. The study focuses on Leukemia. Target enrollment is 9 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing Immunochina Medical Science & Technology Co., Ltd.
Timeline & Enrollment
Phase 1
Jul 11, 2022
Oct 01, 2024
Primary Outcome
Incidence of adverse events (AEs),Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood and bone marrow )
Summary
This is a open-label to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell
 Acute Lymphoblastic Leukemia.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05480501
Non-Device Trial